Diuretics for hypertension: A review and update

American Journal of Hypertension

Volumn 29, Issue 10, 2016, Pages 1130-1137

  Roush, George C ^a   Sica, Domenic A ^b  

^a School of Medicine   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

amiloride; blood pressure; chlorthalidone; eplerenone; hydrochlorothiazide; hypertension; indapamide; potassium sparing diuretics; sodium chloride symporter inhibitors; spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; EPLERENONE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LACIDIPINE; LISINOPRIL; LOOP DIURETIC AGENT; POTASSIUM SPARING DIURETIC AGENT; PTERIDINE DERIVATIVE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; TRIAMTERENE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CALCIUM BLOOD LEVEL; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG POTENCY; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; FLATULENCE; GLUCOSE BLOOD LEVEL; GOUT; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; LIBIDO DISORDER; META ANALYSIS (TOPIC); METABOLIC ALKALOSIS; METABOLIC DISORDER; NAUSEA; NEPHROLITHIASIS; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESISTANT HYPERTENSION; REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

DIURETICS; HUMANS; HYPERTENSION;

EID: 84973628193     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpw030     Document Type: Review

References (69)

1. Moser M, Feig PU. Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med 2009; 169: 1851-1856
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034
3. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA 2015; 314: 1818-1831
4. Felder RA, White MJ, Williams SM, Jose PA. Diagnostic tools for hypertension and salt sensitivity testing. Curr Opin Nephrol Hypertens 2013; 22: 65-76
5. Kusche-Vihrog K, Oberleithner H. An emerging concept of vascular salt sensitivity. F1000 Biol Rep 2012; 4: 439-442
6. Castiglioni P, Parati G, Brambilla L, Brambilla V, Gualerzi M, Di Rienzo M, Coruzzi P. A new index of sodium sensitivity risk from arterial blood pressure monitoring during habitual salt intake. Int J Cardiol 2013; 168: 4523-4525
7. Sica DA. Thiazide and loop diuretics. In Izzo Jr, JL, Black HR, Sica DA (eds), Hypertension Primer, Vol 441. American Heart Association: Dallas, TX, 2008, pp. 439-442
8. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-Analysis. JAMA 2003; 289: 2534-2544
9. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009, 3. CD001841
10. National Heart Foundation of Australia. Guide to the Management of Hypertension: Assessing and Managing Raised Blood Pressure in Adults. 2008, [Updated 2010
11. Canadian Hypertension Education Program (CHEP). 2014. Accessed 9 July 2014
12. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
13. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, Flack JM, Carter BL, Materson BJ, Ram CV, Cohen DL, Cadet JC, Jean-Charles RR, Taler S, Kountz D, Townsend RR, Chalmers J, Ramirez AJ, Bakris GL, Wang J, Schutte AE, Bisognano JD, Touyz RM, Sica D, Harrap SB. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014; 16: 14-26
14. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520
15. National Institute for Health and Clinical Excellence. Hypertension: Clinical Management of Primary Hypertension in Adults. Royal College of Physicians (UK): London, 2011
16. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-1419
17. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. International Society on Hypertension in Blacks. Management of high blood pressure in blacks: an update on the International Society on Hypertension in Blacks Consensus Statement. Hypertension 2010; 56: 780-800
18. Roush GC, Ernst ME, Kostis JB, Kaur R, Sica DA. Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. Curr Hypertens Rep 2015; 17: 1-11
19. Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-Analyses. J Hypertens 2016; 34: 11-19
20. Anderson J, Godfrey BE, Hill DM, Munro-Faure AD, Sheldon J. A comparison of the effects of hydrochlorothiazide and of frusemide in the treatment of hypertensive patients. Q J Med 1971; 40: 541-560
21. Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology 1994; 84(Suppl 2): 36-42
22. Spannbrucker N, Achhammer I, Metz P, Glocke M. Comparative study on the antihypertensive efficacy of torasemide and indapamide in patients with essential hypertension. Arzneimittelforschung 1988; 38: 190-193
23. Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo Study data. Am J Med 1986; 80: 3-6
24. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. NEJM 2003; 348: 583-592
25. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. NEJM 2008; 359: 2417-2428
26. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-Analyses. Hypertension 2012; 59: 1110-1117
27. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255-3264
28. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic versus alpha blocker as first-step antihypertensive therapy. Final results from the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 2003; 42: 239-246
29. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997
30. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A; SHELL Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160-167
31. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108: 710-717
32. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-412
33. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-Acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-372
34. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F, Hamdy R, Joossens JV, Lund-Johansen P, Petrie J, Tuomilehto J, Williams B. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985; 1: 1349-1354
35. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-To-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65: 101-1046
36. Kaplan NM. Indapamide: is it the better diuretic for hypertension? Hypertension 2015; 65: 983-984
37. Wilson L, Nair KV, Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich) 2014; 16: 864-868
38. Saseen JJ, Ghushchyan V, Nair KV. Comparing clinical effectiveness and drug toxicity with hydrochlorothiazide and chlorthalidone using two potency ratios in a managed care population. J Clin Hypertens (Greenwich) 2015; 17: 134-140
39. Vinereanu D, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, Cinteza M, Granger C, Ciobanu AO. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: results of a randomized trial. Am Heart J 2014; 168: 446-456
40. Garg R, Rao AD, Baimas-George M, Hurwitz S, Foster C, Shah RV, Jerosch-Herold M, Kwong RY, Di Carli MF, Adler GK. Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015; 64: 236-242
41. Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-Type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-Analysis. Hypertension 2015; 65: 1033-1040
42. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2012; 59: 926-933
43. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, Cushman WC, Ford CE, Margolis KL, Moloo J, Oparil S, Piller LB, Simmons DL, Sweeney ME, Whelton PK, Wong ND, Wright JT Jr; ALLHAT Collaborative Research Group. Long-Term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes 2012; 5: 153-162
44. van Blijderveen JC, Straus SM, Rodenburg EM, Zietse R, Stricker BH, Sturkenboom MC, Verhamme KM. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 2014; 127: 763-771
45. Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, Davis BR. Association between chlorthalidone treatment of systolic hypertension and long-Term survival. JAMA 2011; 306: 2588-2593
46. Kostis WJ, Cabrera J, Messerli FH, Cheng JQ, Sedjro JE, Cosgrove NM, Swerdel JN, Deng Y, Davis BR, Kostis JB. Competing cardiovascular and noncardiovascular risks and longevity in the systolic hypertension in the elderly program. Am J Cardiol 2014; 113: 676-681
47. Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M; ALLHAT Collaborative Research Group. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64: 1012-1021
48. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-To-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study. Ann Intern Med 2015; 163: 329-338
49. Waeber B1, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother 2012; 13: 1515-1526
50. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041
51. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
52. Chalmers J1, Arima H, Woodward M, Mancia G, Poulter N, Hirakawa Y, Zoungas S, Patel A, Williams B, Harrap S. Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action In Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial. Hypertension 2014; 63: 259-264
53. Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, Russell RP. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-Analysis of randomized and nonrandomized studies. Am J Hypertens 2015; 28: 1376-1385
54. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075
55. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217-2226
56. Oxlund CS, Buhl KB, Jacobsen IA, Hansen MR, Gram J, Henriksen JE, Schousboe K, Tarnow L, Jensen BL. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. J Am Soc Hypertens 2014; 8: 872-881
57. Schohn DC, Jahn HA, Pelletier BC. Dose-related cardiovascular effects of spironolactone. Am J Cardiol 1993; 71: 40A-45A
58. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
59. Matsumoto Y, Mori Y, Kageyama S, Arihara K, Sugiyama T, Ohmura H, Yakushigawa T, Sugiyama H, Shimada Y, Nojima Y, Shio N. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528-536
60. Baker WL, White WB. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012; 46: 889-894
61. Morales E, Millet VG, Rojas-Rivera J, Huerta A, Gutiérrez E, Gutiérrez-Solís E, Egido J, Praga M. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013; 28: 405-412
62. Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012; 29: e184-190
63. Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone. Nephrol Dial Transplant 2013; 28: 1787-1793
64. Raheja P, Price A, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Vongpatanasin W. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012; 60: 319-325
65. Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-Analysis. Int J Cardiol 2014; 177: 219-228
66. Fujimura N, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y; ROCK Study Group. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-Associated kinase activity in patients with hypertension. Clin Pharmacol Ther 2012; 91: 289-297
67. Musini VM, Rezapour P, Wright JM, Bassett K, Jauca CD. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. Cochrane Database Syst Rev 2015; 5: CD003825
68. Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernandez JR. Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol Int 2008; 25: 950-970
69. The SPRINT Research Group. A randomized trial of intensive versus standardized blood-pressure control. N Engl J Med 2015; 373: 2103-2116